Tisdag 7 Januari | 02:51:15 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-08-22 09:00 Kvartalsrapport 2025-Q2
2025-05-08 09:00 Kvartalsrapport 2025-Q1
2025-02-20 09:00 Bokslutskommuniké 2024
2024-10-31 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-05-08 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2024-05-07 - ÅrsstĂ€mma
2024-05-07 - Kvartalsrapport 2024-Q1
2024-02-22 - Bokslutskommuniké 2023
2023-10-31 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2023-05-25 - ÅrsstĂ€mma
2023-05-03 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-02 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-30 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2022-05-27 - ÅrsstĂ€mma
2022-05-06 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-24 - Extra BolagsstÀmma 2021
2021-10-20 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2021-05-27 - ÅrsstĂ€mma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-02-17 - Bokslutskommuniké 2020
2020-11-03 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-28 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2020-05-27 - ÅrsstĂ€mma
2020-04-28 - Kvartalsrapport 2020-Q1
2020-02-17 - Bokslutskommuniké 2019
2019-10-31 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-06-04 - ÅrsstĂ€mma
2019-05-23 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2019-04-30 - Kvartalsrapport 2019-Q1
2019-02-15 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHÀlsovÄrd
IndustriMedicinteknik
Lumito specialiserar sig pÄ medicinsk teknik för digital patologi. Bolaget strÀvar efter att förbÀttra vÀvnadsdiagnostiken med sin patenterade teknologi baserad pÄ uppkonverterade nanopartiklar. Bolaget planerar att initialt lansera sin första produkt för forskningslaboratorier. Bolaget bildades under 2010 som en spinoff frÄn en forskargrupp vid Lunds universitets avdelning för atomfysik och lasercentrum. Lumito har sitt huvudkontor i Lund.
2024-11-28 12:00:00

The board of directors of Lumito AB ("Lumito" or the "Company") has decided to refinance parts of existing loan of SEK 20 million excluding interest from Fenja Capital II A/S (the “Existing Loan”) through a new loan of SEK 12.5 million (the “Loan”) from Fenja Capital II A/S (formerly Formue Nord Fokus A/S, the “Lender”). Thus, Lumito repays SEK 7.5 million of the Existing Loan excluding interest to the Lender and refinances the remainder of SEK 12.5 million. Together with the Loan the board of directors have decided to issue warrants of series 2024/2029 (the “Warrants”) to the Lender free of charge as a part of the agreement. The Loan is procured with the aim of accelerating the commercialization of the Company's product portfolio.

In order to accelerate the commercialization of Lumito's product SCIZYS with associated reagent fluids, the Company intends to strengthen its financial resources through the Loan. The Loan is intended to refinance parts of the Existing Loan procured during the fourth quarter of 2023 with a maturity date of December 9, 2024. Lumito will repay SEK 7.5 million of the Existing Loan excluding interest to the Lender and refinance the remainder of SEK 12.5 million.

Summary of the Loan and the Warrarnts

  • The Loan amounts to a total of SEK 12.5 million with a maturity of 12 months from November 30, 2024.
  • At the inception of the Loan, 21,500,000 warrants are also issued to the Lender free of charge. The Warrants can be exercised for subscription of the corresponding number of shares in the Company from the date of registration of the Warrants with the Swedish Companies Registration Office up to and including November 30, 2029, at a subscription price of SEK 0.638 per share.
  • The loan has a set-up fee of 4 percent and carries an interest rate of 1.25 percent per each commenced 30-day period.
  • The Company has the option to repay the Loan at any time during the term.
  • Upon full exercise of the Warrants during or after the term of the Loan, the number of shares and the share capital will increase, resulting in a dilution of approximately 7.48 percent for existing shareholders.

Terms of the Loan and the Warrants
The Loan of SEK 12.5 million has been procured from Fenja Capital II A/S, with a maturity of 12 months from November 30, 2024. In connection with the Loan, 21,500,000 warrants will also be issued to the Lenders free of charge. The Warrants are not intended to be admitted to trading on NGM Nordic SME after final registration with the Swedish Companies Registration Office. The Warrants can be exercised for subscription of the corresponding number of shares in the Company from the date of registration of the Warrants with the Swedish Companies Registration Office up to and including November 30, 2029, at a subscription price of SEK 0.638 per share, which corresponds to 140 percent of Lumito’s share price at close on November 27, 2024. The board of directors has decided to issue the Warrants based on the authorization of the annual general meeting from 7 May 2024.

The Loan has a set-up fee of 4 percent of the total loan amount and carries an interest rate of 1.25 percent per each commenced 30-day period. The Company has the option to repay the Loan at any time during the term.

If all warrants are exercised, the number of shares in the Company will increase by 21,500,000 and the share capital by SEK 537,500.00, which corresponds to a dilution of approximately 7.48 percent.

Advisers
Mangold Fondkommission AB is financial adviser and Advokatfirman Lindahl KB is legal advisor Lumito in connection with the Loan and the Warrants.